Who is moving to which position
Resolved 18 March 2026Incoming appointee
2 itemsDeparting officer
1 item“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Continuing in office as Director
This change in representative authority is intended to clarify responsibility for the Company's investment business, as the Company will focus its main business on investment activities effective 1 April. Akinaga Shiro (秋永 士朗) will be responsible for the scientific evaluation of investment target companies and, as Representative Director and President of NANO MRNA株式会社, will oversee the NANO MRNA business. Matsuo Takashi (松尾 隆) will also serve as CFO, in addition to his existing positions as CAO and CCO, to strengthen the finance function in connection with the transition to investment activities.
Effective 1 April 2026, the Company will transition to an investment company structure (investment holding company) and make investment activities its principal business. The Company will establish NANO MRNA株式会社 and launch an investment structure in cooperation with NBI and Nano Holdings US, LLC.
| Item | Details |
|---|---|
| Resolution date | 18 March 2026 |
| Scheduled Appointment Date | Effective 1 April 2026 |
| Date of departure | Effective 1 April 2026 (departure from the position of representative director) |
| Name of appointee | Akinaga Shiro (秋永 士朗), Matsuo Takashi (松尾 隆) |
| Appointee's new position | Director, CTO (without representative authority), Director, CFO / CAO / CCO |
| Appointee's previous position | Representative Director, CTO (with representative authority), Director, CAO / CCO |
| Name of departing officer | Akinaga Shiro (秋永 士朗) |
| Former position of departing officer | Representative Director, CTO (with representative authority) |
| New position of departing officer | Director, CTO (without representative authority) |
| Whether the incumbent will remain in office | Continuing in office as Director |
| Reason for change | This change in representative authority is intended to clarify responsibility for the Company's investment business, as the Company will focus its main business on investment activities effective 1 April. Akinaga Shiro (秋永 士朗) will be responsible for the scientific evaluation of investment target companies and, as Representative Director and President of NANO MRNA株式会社, will oversee the NANO MRNA business. Matsuo Takashi (松尾 隆) will also serve as CFO, in addition to his existing positions as CAO and CCO, to strengthen the finance function in connection with the transition to investment activities. |
| Number of directors after the change | 8 directors (including 2 outside directors) |
| Details of organizational changes | Effective 1 April 2026, the Company will transition to an investment company structure (investment holding company) and make investment activities its principal business. The Company will establish NANO MRNA株式会社 and launch an investment structure in cooperation with NBI and Nano Holdings US, LLC. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.As the Company will focus its main business on investment activities effective 1 April, the change in representative authority is intended to clarify responsibility for this business. Akinaga Shiro (秋永 士朗) will be responsible for the scientific evaluation of investment target companies and the management of NANO MRNA株式会社, while Matsuo Takashi (松尾 隆) will also serve as CFO to strengthen the finance function in connection with the transition to investment activities.